Ovid Therapeutics (NASDAQ:OVID) Stock Crosses Below Fifty Day Moving Average – Here’s Why

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) shares passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $2.50 and traded as low as $2.37. Ovid Therapeutics shares last traded at $2.40, with a volume of 2,796,391 shares traded.

Analysts Set New Price Targets

A number of brokerages recently weighed in on OVID. Guggenheim initiated coverage on shares of Ovid Therapeutics in a report on Tuesday, October 6th. They set a “buy” rating and a $7.00 target price on the stock. UBS Group reiterated a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, September 11th. Roth Capital reissued a “buy” rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a research report on Thursday, September 3rd. HC Wainwright boosted their price objective on shares of Ovid Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Finally, Cantor Fitzgerald began coverage on shares of Ovid Therapeutics in a research note on Friday, October 9th. They set an “overweight” rating on the stock. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.12.

Read Our Latest Report on Ovid Therapeutics

Ovid Therapeutics Stock Down 5.5%

The stock has a market cap of $452.95 million, a P/E ratio of -10.00 and a beta of 0.24. The firm has a 50 day simple moving average of $2.50 and a 200-day simple moving average of $2.40. The company has a quick ratio of 12.39, a current ratio of 11.97 and a debt-to-equity ratio of 0.05.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). On average, equities research analysts forecast that Ovid Therapeutics will post -0.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ovid Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Jupiter Topco LLC acquired a new stake in Ovid Therapeutics during the 2nd quarter valued at $55,898,000. BlackRock Inc. acquired a new position in shares of Ovid Therapeutics in the second quarter valued at $29,115,000. Janus Henderson Group PLC acquired a new position in shares of Ovid Therapeutics in the first quarter valued at $23,732,000. Affinity Asset Advisors LLC increased its holdings in shares of Ovid Therapeutics by 48.8% in the first quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock valued at $23,613,000 after purchasing an additional 3,486,318 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of Ovid Therapeutics in the second quarter valued at about $19,953,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

Featured Articles

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.